Want to see MIST full AI Analyst Report?
MIST Stock Chart & Stats
$1.19
-$0.03(-2.59%)
At close: 4:00 PM EDT
$1.19
-$0.03(-2.59%)
Day’s Range― - ―
52-Week Range$0.71 - $3.06
Previous Close$1.14
Volume1.21M
Average Volume (3M)1.29M
Market Cap
$95.24M
Enterprise Value$157.07M
Total Cash (Recent Filing)$170.61M
Total Debt (Recent Filing)$141.83M
Price to Earnings (P/E)―
Beta3.03
Next Earnings
Nov 17, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.69
Shares Outstanding124,497,980
10 Day Avg. Volume1,013,967
30 Day Avg. Volume1,294,108
Financial Highlights & Ratios
PEG Ratio-0.23
Price to Book (P/B)4.06
Price to Sales (P/S)109.60
P/FCF Ratio-3.43
Enterprise Value/Market Cap1.65
Enterprise Value/Revenue67.04
Enterprise Value/Gross Profit70.88
Enterprise Value/Ebitda-2.15
Forecast
1Y Price Target
$6.50Price Target Upside446.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.84
Revenue Forecast (FY)$3.83M
Bulls Say, Bears Say
Bulls Say
Early Commercial AdoptionRapid growth in prescriptions, prescribers, and treated patients provides evidence that CARDAMYST is gaining real-world adoption after launch. Emerging repeat use is particularly important because it suggests potential for recurring demand rather than reliance solely on initial trial prescriptions.
Expanding Payer CoverageBroader formulary access can reduce denials, improve payer pull-through, and support higher realized selling prices. Because commercial insurance represents about 45% of the PSVT population, continued coverage gains could materially improve the commercial economics of the lead product.
International Regulatory ExpansionChina approval creates the first regulatory authorization for etripamil outside the United States and establishes an additional commercialization pathway through Everest Medicines. Milestone payments and potential royalties could broaden future revenue sources without requiring all regional commercialization investment internally.
Bears Say
Large Losses And Cash BurnThe company remains far from self-funding because losses and cash outflows are substantial relative to its approximately $2.3 million TTM revenue base. Persistent burn increases dependence on future financing and leaves less flexibility to fund development or commercial expansion.
High Leverage And Reduced Equity BufferHigh leverage combined with a sharply reduced equity base weakens financial resilience while the business is still loss-making. Continued operating losses could further erode the buffer, increasing financing pressure and limiting management’s flexibility in allocating capital.
Reimbursement And Trial Execution DependenceCommercial expansion still depends on the timing and breadth of payer coverage, including Medicare, so access improvements may not translate into revenue immediately. Separately, endpoint and event-classification risks in Phase III could delay or weaken expansion into the larger AFib-RVR opportunity.
Milestone Pharmaceuticals News
MIST FAQ
What was Milestone Pharmaceuticals’s price range in the past 12 months?
Milestone Pharmaceuticals lowest stock price was $0.71 and its highest was $3.06 in the past 12 months.
What is Milestone Pharmaceuticals’s market cap?
Milestone Pharmaceuticals’s market cap is $95.24M.
When is Milestone Pharmaceuticals’s upcoming earnings report date?
Milestone Pharmaceuticals’s upcoming earnings report date is Nov 17, 2026 which is in 36 days.
How were Milestone Pharmaceuticals’s earnings last quarter?
Milestone Pharmaceuticals released its earnings results on Aug 12, 2026. The company reported -$0.21 earnings per share for the quarter, missing the consensus estimate of -$0.195 by -$0.015.
Is Milestone Pharmaceuticals overvalued?
According to Wall Street analysts Milestone Pharmaceuticals’s price is currently Undervalued.
Does Milestone Pharmaceuticals pay dividends?
Milestone Pharmaceuticals does not currently pay dividends.
What is Milestone Pharmaceuticals’s EPS estimate?
Milestone Pharmaceuticals’s EPS estimate is -0.22.
How many shares outstanding does Milestone Pharmaceuticals have?
Milestone Pharmaceuticals has 124,497,980 shares outstanding.
What happened to Milestone Pharmaceuticals’s price movement after its last earnings report?
Milestone Pharmaceuticals reported an EPS of -$0.21 in its last earnings report, missing expectations of -$0.195. Following the earnings report the stock price went down -11.417%.
Which hedge fund is a major shareholder of Milestone Pharmaceuticals?
Currently, no hedge funds are holding shares in MIST
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Milestone Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.50 (446.22% Upside)
$6.50 (446.22% Upside)
Blogger Sentiment
Neutral
MIST Sentiment 50%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 133.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 3.4%
Last 30 Days ▼ 3.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-63.39%
12-Months-Change
Fundamentals
Return on Equity
-288.36%
Trailing 12-Months
Asset Growth
283.04%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, specializing in the creation and commercialization of cardiovascular therapeutics. Their flagship product, etripamil, an innovative channel blocker, is currently in advanced clinical development. It is undergoing Phase III trials for the treatment of paroxysmal supraventricular tachycardia (PSVT) in the United States and Canada, while also progressing through Phase II trials for atrial fibrillation and rapid ventricular rate. Furthermore, Milestone Pharmaceuticals has forged a licensing and collaboration alliance with Ji Xing Pharmaceuticals to advance and distribute etripamil for both preventative and therapeutic applications in humans. The company was founded in 2003.
MIST Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed clear early commercial momentum and important strategic progress: rapid increases in prescribers and prescriptions, a recent and meaningful expansion of commercial formulary coverage to ~50%, initiation of a pivotal Phase III AFib-RVR trial, and a healthy cash position (≈$170.6M) with runway into H2 2027. Offsetting these positives are material near-term financial pressures — minimal product revenue to date, heavy SG&A related to the launch, widening net losses, and dependencies on payer decisions and trial execution (notably patient-reported endpoints and event misclassification risk). Overall the company appears to be in a typical early-launch, high-investment phase with encouraging uptake signals and defined paths to improve revenue as coverage and ASPs normalize, but substantial execution and reimbursement risks remain.View all MIST earnings summariesMIST Stock 12 Month Forecast
Average Price Target
$6.50
▲(446.22% Upside)
Technical Analysis
Corbus Pharmaceuticals
―
Seres Therapeutics
―
Avalo Therapeutics
―
Elicio Therapeutics
―
Alto Neuroscience, Inc.
―
Ownership Overview
0.88% Insiders
0.06% Mutual Funds
1.04% Other Institutional Investors
95.31% Public Companies and
Individual Investors